ArticleFrontiers in cellular and infection microbiology2026
Preoperative gut microbiota combined with machine learning for predicting post-hepatectomy liver failure in HBV-related hepatocellular carcinoma: a pilot study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the association between preoperative gut microbiota (GM) profiles and post-hepatectomy liver failure (PHLF) in patients with newly diagnosed HBV-related hepatocellular carcinoma (HBV-HCC), aiming to explore non-invasive, modifiable GM biomarkers for perioperative risk stratification. Methods: A total of 233 fecal samples underwent 16S rRNA sequencing and were stratified into three distinct sets: a training set ( Results: Significant β-diversity differences (Weighted UniFrac) were observed between the groups, identifying 11 differential genera; PHLF patients exhibited a characteristic enrichment of Faecalibacterium, and Blautia, alongside a profound depletion of Bacteroides. Functional inferences revealed distinct metabolic remodeling in the PHLF group, characterized by the upregulation of amino acid biosynthesis (specifically lysine and arginine) and nucleoside catabolism, coupled with a prominent downregulation of the hepatic-interactive urea cycle, central carbon metabolism (glycolysis and tricarboxylic acid [TCA] cycle), and short-chain fatty acid [SCFA] (butyrate) metabolism. In the independent external validation set, the XGBoost, RF, and GBM models achieved areas under the receiver operating characteristic curve (AUCs) of 78.12%, 71.88%, and 63.54%, respectively. Importantly, the models showed potent exclusionary performance, with specificities of 81.25% for XGBoost and RF versus 72.22% for GBM, while all three maintained a stable negative predictive value (NPV) of 81.25% and exceptionally stable negative F1-scores (F1- negative).Decision curve analysis (DCA) confirmed notable clinical net benefit of all models. Conclusion: We are among the first to characterize distinct GM signatures in PHLF patients with cross-geographic reproducibility. GM demonstrates strong potential as a non-invasive tool for preoperative risk stratification targeting the primary endpoint of PHLF. Characterized by high specificity and potent exclusionary capacity, this signature establishes a clinically robust framework for accurate low-risk patient identification and triage, thereby optimizing perioperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.